Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
$1.51
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.51
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$94.02M
Enterprise Value$102.70M
Total Cash (Recent Filing)$77.73M
Total Debt (Recent Filing)$19.07M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 25, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding62,264,214
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.76
Price to Sales (P/S)5.65
P/FCF Ratio-1.57
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue36.42
Enterprise Value/Gross Profit36.42
Enterprise Value/Ebitda-1.26
Forecast
1Y Price Target
$6.90Price Target Upside356.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyConfirmed objective response rates in later‑line head and neck cancer, including a 60% ORR in certain monotherapy cohorts and a 71% ORR in combination cohorts, demonstrate strong clinical activity that could strengthen competitive positioning.
Leadership And Commercialization FocusInterim CEO's deep commercialization and transaction experience suggests a stronger emphasis on advancing the clinical program and articulating the asset's commercial value to potential partners or acquirers.
Partnerships And Business DevelopmentAn established clinical collaboration with Merck and renewed acquirer interest in antibody‑drug conjugate oncology assets increase the likelihood of partnership or acquisition opportunities for the program.
Bears Say
Clinical Development And Enrollment RiskSlow enrollment and small cohort sizes produce ambiguous readouts, increasing the risk of delayed milestones or inconclusive data that may unsettle investors.
Financial Runway And Market ReactionA limited cash runway of about one year combined with a sharp share price decline following clinical uncertainties could constrain operational flexibility and force consideration of dilutive financing or urgent partnerships.
Safety And TolerabilityGrade 3 treatment‑related adverse events and a 28% discontinuation rate raise tolerability concerns that could hinder patient retention in trials and weaken eventual market adoption.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $94.02M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Mar 25, 2026 which is in 48 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.34.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 62,264,214 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.90 (356.95% Upside)
$6.90 (356.95% Upside)
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.3%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
-45.93%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.90
▲(356.95% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.26%
Insiders
3.80% Mutual Funds
0.04% Other Institutional Investors
81.77% Public Companies and Individual Investors